Download App

Log in to access Online Inquiry
Company Overview More
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
CEO: Harris Ph.D., Todd
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

TYRA TYRA BIOSCIENCES, INC.

7.920+0.250+3.26%
Close 05/27 20:00 ET
7.92000.00%
Post Mkt Price 05/27 16:01 ET
High
8.150
Open
7.630
Turnover
383.66K
Low
7.450
Pre Close
7.670
Volume
48.79K
Market Cap
330.75M
P/E(TTM)
Loss
52wk High
31.360
Shares
41.76M
P/E(Static)
Loss
52wk Low
6.250
Float Cap
86.73M
Bid/Ask %
0.00%
Historical High
31.360
Shs Float
10.95M
Volume Ratio
0.76
Historical Low
6.250
Dividend TTM
--
Div Yield TTM
--
P/B
1.14
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.45%
Amplitude
9.13%
Avg Price
7.862
Lot Size
1
Float Cap
86.73M
Bid/Ask %
0.00%
Historical High
31.360
Shs Float
10.95M
Volume Ratio
0.76
Historical Low
6.250
Dividend TTM
--
P/B
1.14
Dividend LFY
--
Turnover Ratio
0.45%
Amplitude
9.13%
Avg Price
7.862
Lot Size
1
Price Forecast

No Data

News

Comment